Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that ...

Dragged down by negative returns for shares of Amgen and Amazon.com Inc., the Dow Jones Industrial Average is declining Friday afternoon.

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

Shares of Merck Merck & Co. Inc. and Amgen Amgen Inc. are contributing to the blue-chip gauge's intraday decline, as the Dow Dow Jones Industrial Average was most recently trading 168 points, or 0.4%, ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...